Accord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patients
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today a partnership with…
Accord BioPharma and EVERSANA Announce Partnership to Support the Launch of CAMCEVI® for the Treatment of Advanced Prostate Cancer in Adults in the U.S.
EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, and Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., today announced…
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
– U.S. Launch Supported by Accord BioPharma’s parent company, Intas Pharmaceuticals – DURHAM, N.C., April 4, 2022 /PRNewswire/ — Accord BioPharma, the U.S. specialty division of Intas…
Accord BioPharma Announces U.S. Launch for CAMCEVI™ (Leuprolide) Injection Emulsion for the Treatment of Advanced Prostate Cancer in Adults
– CAMCEVI™ is the first ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection that comes in a pre-filled syringe with no mixing required – DURHAM, N.C., March…
